A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This multi-center, randomized, double-blind, placebo-controlled study, conducted in Turkey,
will assess the efficacy and safety of topical SM04554 solution (0.15% and 0.25%) applied
daily to the scalp of male androgenetic alopecia (AGA) subjects.